RxDoctor Payments Data

Glenna Burton, MD

Psychiatry · Columbia, MONPI 1336174283

Payments from drug & device makers

$2,210in general payments, 2019–2025

Across 105 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$510
  • Teva Pharmaceuticals USA, Inc.$405
  • AbbVie$310
  • Neurocrine Biosciences, Inc.$290
  • Axsome Therapeutics, Inc.$266
  • Alkermes, Inc.$261
  • plus $169 from 6 others

What the payments were for

  • Food & beverage$2,09995%
  • Education$1115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,210 in reported general payments places this provider in the 75th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$43,234
Medicare patients
15
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl102$98,863
VraylarCariprazine Hcl17$24,325
TrintellixVortioxetine Hydrobromide25$11,039
Galantamine Hbr64$3,699
Venlafaxine Hcl ErVenlafaxine Hcl94$3,437
LoxapineLoxapine Succinate17$1,661
Prazosin Hcl89$1,611
Vilazodone Hcl20$1,471
Amoxapine29$1,348
Trazodone Hcl21$1,336
Memantine Hcl75$1,115
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine43$1,102
Bupropion XlBupropion Hcl95$1,058
Duloxetine Hcl38$523
Quetiapine Fumarate30$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$510$98,863102 claims
AbbVieVraylar$310$24,32517 claims
Teva Pharmaceuticals USA, Inc.Loxapine$405$1,66117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →